[go: up one dir, main page]

Devreese et al., 2011 - Google Patents

Anticardiolipin and anti-β2glycoprotein-I antibody cut-off values in the diagnosis of antiphospholipid syndrome: more than calculating the in-house 99th percentiles …

Devreese et al., 2011

Document ID
2565218509707336266
Author
Devreese K
Van Hoecke F
Publication year
Publication venue
Thrombosis research

External Links

Snippet

The laboratory criteria for the antiphospholipid syndrome (APS) include lupus anticoagulants (LAC), medium or high titer (N40 GPL or MPL, or N99th percentile) anticardiolipin antibodies (aCL) or anti-β2-glycoprotein I antibodies (aβ2GPI)(N99th …
Continue reading at www.thrombosisresearch.com (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/564Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/543Immunoassay; Biospecific binding assay with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306Solid-phase reaction mechanisms
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRICAL DIGITAL DATA PROCESSING
    • G06F17/00Digital computing or data processing equipment or methods, specially adapted for specific functions
    • G06F17/30Information retrieval; Database structures therefor; File system structures therefor
    • G06F17/30861Retrieval from the Internet, e.g. browsers
    • G06F17/30864Retrieval from the Internet, e.g. browsers by querying, e.g. search engines or meta-search engines, crawling techniques, push systems
    • G06F17/30867Retrieval from the Internet, e.g. browsers by querying, e.g. search engines or meta-search engines, crawling techniques, push systems with filtering and personalisation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRICAL DIGITAL DATA PROCESSING
    • G06F17/00Digital computing or data processing equipment or methods, specially adapted for specific functions
    • G06F17/30Information retrieval; Database structures therefor; File system structures therefor
    • G06F17/30286Information retrieval; Database structures therefor; File system structures therefor in structured data stores
    • G06F17/30386Retrieval requests
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRICAL DIGITAL DATA PROCESSING
    • G06F9/00Arrangements for programme control, e.g. control unit
    • G06F9/06Arrangements for programme control, e.g. control unit using stored programme, i.e. using internal store of processing equipment to receive and retain programme
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00Digital computing or data processing equipment or methods, specially adapted for specific applications
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases

Similar Documents

Publication Publication Date Title
Devreese et al. Anticardiolipin and anti-β2glycoprotein-I antibody cut-off values in the diagnosis of antiphospholipid syndrome: more than calculating the in-house 99th percentiles, even for new automated assays
Reber et al. Proposals for the measurement of anti‐β2‐glycoprotein I antibodies. Standardization Group of the European Forum on Antiphospholipid Antibodies
Galli et al. Invitation to a debate on the serological criteria that define the antiphospholipid syndrome
Chayoua et al. Detection of anti-cardiolipin and anti-β2glycoprotein I antibodies differs between platforms without influence on association with clinical symptoms
Hovinga et al. Measurement of ADAMTS‐13 activity in plasma by the FRETS‐VWF73 assay: comparison with other assay methods
Favaloro et al. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part I—Anticardiolipin and anti-β2-glycoprotein I antibodies
Chayoua et al. Is there an additional value in detecting anticardiolipin and anti-β2 glycoprotein I IgA antibodies in the antiphospholipid syndrome?
Montaruli et al. Analytical and clinical comparison of different immunoassay systems for the detection of antiphospholipid antibodies
Alkema et al. Autoantibody profiles in systemic sclerosis; a comparison of diagnostic tests
Chiang et al. Screening for Wiskott-Aldrich syndrome by flow cytometry
Heikal et al. Laboratory evaluation of anti-phospholipid syndrome: a preliminary prospective study of phosphatidylserine/prothrombin antibodies in an at-risk patient cohort
Echeverri et al. Neutrophil CD64 expression, procalcitonin and presepsin are useful to differentiate infections from flares in SLE patients with SIRS
Kuwana et al. Detection of circulating B cells secreting platelet-specific autoantibody is useful in the diagnosis of autoimmune thrombocytopenia
Wilke et al. Diagnostic performance of point-of-care and central laboratory cardiac troponin assays in an emergency department
Favaloro et al. Laboratory investigation of lupus anticoagulants: mixing studies are sometimes required
Warkentin et al. The use of well‐characterized sera for the assessment of new diagnostic enzyme‐immunoassays for the diagnosis of heparin‐induced thrombocytopenia
De Laat et al. High‐avidity anti‐β2 glycoprotein I antibodies highly correlate with thrombosis in contrast to low‐avidity anti‐β2 glycoprotein I antibodies
Chung et al. Clinical performance of anticardiolipin and antiβ2 glycoprotein I antibodies using a new automated chemiluminescent assay: superior thrombotic prediction of combined results measured by two different methods
Favaloro et al. Variability in D-dimer reporting revisited
Chandler et al. Lupus anticoagulant testing and anticoagulation do not mix: quantitation of discrepant results and potential approaches to reduce false positives
Jennings et al. ISTH/SSC lupus anticoagulant testing guidelines: how far have these been adopted by laboratories?
Mohloanyane et al. Recent HIV infections among newly diagnosed individuals living with HIV in rural Lesotho: Secondary data from the VIBRA cluster-randomized trial
Wong et al. A consensus approach to the formulation of guidelines for laboratory testing and reporting of antiphospholipid antibody assays
Podolsky et al. Choosing which in-hospital laboratory tests to target for intervention: a scoping review
Bor et al. Revisiting the Phadia/EliA cut-off values for anticardiolipin and anti-β2-glycoprotein I antibodies: a systematic evaluation according to the guidelines